Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis

Area of Science:

• Hepatology
• Gastroenterology
• Clinical Pharmacology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic bile duct disease with unknown causes and few treatment options.
• Current treatments for PSC lack confirmed efficacy and safety, necessitating further research.
• Previous clinical trials have targeted various pathways, including bile acid signaling and gut microbiota, with limited success.

Purpose of the Study:

• To review ongoing and completed clinical trials for PSC (Phase II and beyond).
• To discuss potential therapeutic targets and strategies for PSC treatment.
• To identify limitations and future directions in PSC drug development.

Main Methods:

• Literature search of PubMed and ClinicalTrials.gov for PSC clinical trials.
• Included studies were Phase II or later.
• Keywords included 'primary sclerosing cholangitis,' 'clinical trials,' 'antibiotics,' and specific drug names.

Main Results:

• Vancomycin therapy demonstrated promising results in a Phase III clinical trial for PSC.
• Most other drug candidates evaluated in clinical trials showed futility or inconsistent outcomes.
• The search for effective and safe PSC treatments remains active.

Conclusions:

• Vancomycin represents a potential therapeutic option for PSC, warranting further investigation.
• Developing novel treatments for PSC is critical due to the limited efficacy of current options.
• Continued research into therapeutic targets and strategies is essential for advancing PSC care.